BioLineRx (NASDAQ:BLRX) Shares to Reverse Split on Thursday, January 30th

BioLineRx Ltd. (NASDAQ:BLRX) shares are scheduled to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.

BioLineRx Stock Down 5.7 %

Shares of BLRX stock opened at $0.11 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 1 year low of $0.08 and a 1 year high of $1.44. The firm’s fifty day moving average price is $0.23 and its two-hundred day moving average price is $0.48. The firm has a market capitalization of $8.74 million, a P/E ratio of -0.50 and a beta of 1.46.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. On average, equities analysts predict that BioLineRx will post -0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BLRX. StockNews.com began coverage on shares of BioLineRx in a research note on Sunday, January 19th. They set a “hold” rating on the stock. HC Wainwright cut their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

Hedge Funds Weigh In On BioLineRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. PVG Asset Management Corp bought a new stake in BioLineRx during the second quarter valued at approximately $70,000. Atria Investments Inc lifted its position in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC bought a new stake in BioLineRx during the second quarter valued at approximately $462,000. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.